';
The Pennsylvania Department of Drug and Alcohol Programs (DDAP) released Information Bulletin 01-22 today. The purpose of the bulletin is to remind all recovery houses in Pennsylvania, as well as entities who refer individuals to recovery houses, of several requirements of the recovery house law (Act 59 of 2017). A letter from DDAP Secretary Jennifer Smith communicating details of the bulletin was issued today to all stakeholders, as well.
A message from the Department of Human Services (DHS):
Attention Personal Care Services (PCS) and Home Health Care Services (HHCS) Providers:
DHS would like to announce that the Alternate EVV Technical Specifications and updated Sandata Alternate EVV Error Handling Overview and Reference Guide are available online for your review prior to the upcoming Alternate EVV Town Hall on April 11, 2022, at 1:00 pm ET (visit here to register). There will be a second session held May 27, 2022, at 12:00 pm ET for any additional questions that may arise.
All Alternate EVV vendors will need to be certified following the new Alternate EVV Technical Specifications published March 30, 2022. Vendors are expected to review the technical specifications document in its entirety and submit any questions during your registration to the Alternate EVV Town Hall.
If a vendor is not certified (due to being new to EVV) or recertified, the EVV visits will not be accepted for any provider agency the vendor supports. For PCS, the claims or encounters will deny because visit data would not be accepted as a result of the vendor not being recertified.
DHS recommends providers work with their EVV vendor to complete system updates to allow for sufficient time to complete integration testing and the recertification process prior to the Sandata EVV Release. The deployment date is currently expected to be on June 15, 2022. Any changes to this date will be communicated in a future Listserv. The initial certification process can be lengthy, and vendors should prepare accordingly. The minimum recommended time is 7.5 business weeks.
Further contact information for recertification will be provided at the Alternate EVV Town Hall on April 11, 2022.
Join RCPA as we host the 2022 Annual Conference: Together, October 11–14, at the Hershey Lodge. RCPA staff and the Conference Committee are excited to release this year’s Sponsors, Exhibitors, and Advertisers brochure, with new opportunities to get in on the action. Booth self-selection will be back this year for the exhibitors and exhibiting sponsors who submit their contracts with payment by April 29. In order to be considered for self-selection, a completed contract with payment must be submitted.
Don’t miss your chance to be seen and to support the work of this dynamic organization! The event is a highlight for the Pennsylvania mental health, drug and alcohol, intellectual and developmental disabilities, children’s, brain injury, medical rehabilitation, and physical disabilities and aging provider communities.
Connections Hall Brings Us Together
Exhibit activities take place during the two busiest days of the conference, with many networking opportunities throughout the event. Check out the Connections Hall web page for more details!
Exciting New Sponsorship Opportunities
The association is privileged to have the backing of the finest organizations in the field for our conference. Through the use of sponsorship circles, RCPA is able to honor all supporting organizations. Visit the Sponsors page to view opportunities and available sponsorship circles!
Sign Up Now
The deadline for inclusion in all digital materials is August 11. Sponsors, exhibitors, and advertisers who wish to be listed on the website, the mobile app, and in the conference program must adhere to that deadline. The association looks forward to welcoming you at the conference! Space and opportunities are reserved on a first-come, first-served basis, and no reservation is considered complete without payment. If questions remain, please contact Sarah Eyster or Carol Ferenz, Conference Coordinators.
Today, the Departments of Drug and Alcohol Programs (DDAP) and Community & Economic Development (DCED) announced the availability of more than $1 million in grant funding for recovery houses to provide safe housing for individuals in recovery from a substance use disorder (SUD).
Read the press release for more details about the application process.
With Senate Bill 1019 passed into law as Act 14, the Department of Drug and Alcohol’s (DDAP) regulatory suspensions are also extended. These regulatory suspensions are “related to federal exemptions granted under the federal public health emergency declaration” until “the last day federal exemptions granted under the federal public health emergency declaration are authorized.” In addition to three DDAP regulatory suspensions, one additional regulation from the Department of State, also relevant to the field, is included in the chart below and also remains suspended.
Statute/Regulation | Statute/Regulation Purpose |
Waiver Benefit/Explanation |
28 Pa. Code § 715.16(e) |
Prohibits narcotic treatment programs (NTPs — methadone clinics) from permitting a patient to receive more than a 2-week take-home supply of medication | In response to COVID-19, SAMHSA is allowing up to 28 days of take-home medications for patients on stable dosages, if the physician deems appropriate. |
28 Pa. Code § 715.9(a)(4) | Requires NTPs to make a face-to-face determination before admission to treatment, for those clients who will receive buprenorphine treatment. | In response to COVID-19, SAMHSA is allowing initial evaluations for a patient who will be treated with buprenorphine to be completed via telehealth. |
28 Pa. Code § 715.6(d) | Requires NTPs to have narcotic treatment physician services onsite. | In response to COVID-19, SAMHSA is allowing initial evaluations for a patient who will be treated with buprenorphine to be completed via telehealth. |
49 Pa. Code § 16.92(b)(1)
(Department of State) |
Before a patient can be prescribed any controlled substance in Pennsylvania, a person licensed to practice medicine and surgery in the commonwealth, or otherwise licensed or regulated by the State Board of Medicine, must take an initial medical history and conduct an initial physical examination, unless emergency circumstances justify otherwise. |
In response to COVID-19, the Department of State suspended the initial medical history and physical examination requirement specifically for the treatment of opioid-use disorder with buprenorphine. |
In November 2021, the Substance Abuse and Mental Health Services Administration (SAMHSA) announced that the methadone take-home flexibilities will be extended for one year after the eventual expiration of the federal COVID-19 Public Health Emergency. DDAP has submitted its written concurrence with this exemption. SAMHSA has also indicated that they are currently considering mechanisms to make this flexibility permanent. Narcotic treatment programs do not need to do anything additional at this time to continue taking advantage of this flexibility.
Similarly, the U.S. Drug Enforcement Administration (DEA) also announced last week that they are currently working to make their teleprescribing regulations permanent. DDAP will continue to provide additional information and guidance as it becomes available.
If you have any further questions, please contact the Bureau of Program Licensure at (717) 783-8675 or via email.